Clinical trials: Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH)
Study of Median Lobe Prostatic UroLift Procedure
The purpose of this study is to evaluate the safety and effectiveness of using UroLift in subjects with a prostatic median lobe enlargement due to benign prostatic hyperplasia (BPH).
- Trial name
- NCT02625545
- Testing
- UroLift System procedure
- Volunteers
- 45 people
- Sponsor
- NeoTract, Inc.
Prostatic Hyperplasia, Benign Prostatic Hyperplasia
Rezum I Pilot Study for Benign Prostatic Hyperplasia
Evaluate the safety and efficacy of the Rezum System for the treatment of BPH
- Conditions
- Prostatic Hyperplasia, Benign Prostatic Hyperplasia, Adenoma, Prostatic, Prostatic Adenoma
- Trial name
- Rezum Pilot (NCT02943070)
- Testing
- Rezum System
- Where
- 3 sites in Czechia, Dominican Republic and 1 more
- Volunteers
- 50 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Primary: To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients with lower urinary tract symptoms related to BPH.
- Trial name
- NCT00347061
- Testing
- afuzosin
- Where
- Japan
- Volunteers
- 148 people
- Sponsor
- Sanofi
BPH
Efficacy of Prunus Domestica Extract in BPH
Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate Prunus domestica bark contains three groups of active constituents: phytosterols (including beta-sitosterol), pentacyclic triterpenoids (including…
- Trial name
- NCT02702947
- Testing
- Prunus domestica extract
- Where
- India
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Chemical Resources
BPH (Benign Prostatic Hyperplasia), BPH
INTUPRO in the Treatment of Benign Prostatic Hyperplasia-Related Symptoms
The goal of this clinical trial is to determine whether INTUPRO can improve the quality of life in patients with Benign Prostate Hyperplasia (BPH).
- Conditions
- BPH (Benign Prostatic Hyperplasia), BPH, BPH With Other Lower Urinary Tract Symptoms
- Trial name
- NCT07381127
- Testing
- INTUPRO ionic fluid
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- inTumo Therapeutics, Inc.
Prostatic Hyperplasia
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
Patient-based surveys will be conducted to evaluate the drivers of medication adherence in patients treated with either 5-alpha-reductase inhibitor (5ARI) therapy, alpha-blocker (AB) therapy, or combination therapy for enlarged…
- Trial name
- NCT01390870
- Testing
- 5ARI or AB or Combination Therapy (5ARI + AB)
- Volunteers
- 400 people
- Sponsor
- GlaxoSmithKline
Prostate Disease, BPH
Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate)
Multi-center, prospective randomized dosing and safety research study. A maximum of 150 men will be enrolled in the study. Qualifying patients will receive one of three possible doses of the study drug.
- Conditions
- Prostate Disease, BPH, Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00037141
- Testing
- dehydrated alcohol
- Volunteers
- 150 people
- Sponsor
- American Medical Systems
Benign Prostatic Hyperplasia, Erectile Dysfunction
The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction
The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a randomized, double blinded, parallel design, active…
- Trial name
- NCT02862483
- Testing
- Tamsulosin 0.2mg, Tadalafil 5mg
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Prostatic Hyperplasia
SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the volunteers receive, in each period, the test formulation or the reference formulation, under…
- Trial name
- NCT01330303
- Testing
- Reference formulation, Test formulation
- Where
- Brazil
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
The Zenflow Spring System Safety and Performance Study (ZEST CAN)
The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT04309695
- Testing
- Zenflow Spring System
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Zenflow, Inc.
Benign Prostatic Hyperplasia, Overactive Bladder
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
The purpose of the study was to assess the efficacy, safety, and tolerability of mirabegron versus placebo in men with overactive bladder (OAB) symptoms while taking tamsulosin hydrochloride for lower urinary tract symptoms…
- Trial name
- PLUS (NCT02757768)
- Testing
- Mirabegron, Tamsulosin Hydrochloride
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 715 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Benign Prostatic Hyperplasia (BPH)
Post-Market Study to Assess iTind Safety in Comparison to UroLift
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
- Trial name
- MT-08 (NCT04757116)
- Testing
- iTind, UroLift
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 256 people
- Sponsor
- Olympus Corporation of the Americas
Prostatic Hyperplasia
Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)
Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment
- Trial name
- NCT02244333
- Testing
- ALNA®
- Volunteers
- 4,575 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
A Study in Men With Benign Prostatic Hyperplasia
The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)
- Trial name
- NCT01097707
- Testing
- LY500307
- Where
- 70 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- Eli Lilly and Company
BPH/LUTS/Sexual Functions
Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy
To collect under daily practice conditions, clinical data on the changes of sexual function when a new formulation of alfuzosin(Xatral XL® )is administered once daily in patients with lower urinary tract symptoms(LUTS) suggestive…
- Trial name
- NCT00542165
- Testing
- Alfuzosin
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Sanofi
Erectile Dysfunction, Prostatic Hyperplasia
Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers
To investigate the pharmacokinetic properties and safety after administration of HCP1303 and co-administration of HGP1201, HIP1402 in healthy male volunteers
- Trial name
- NCT02712411
- Testing
- HCP1303, HGP1201, HIP1402
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Treatment of Benign Prostatic Hyperplasia
Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH
Twenty (20) subjects presenting with a hyperplasia enlarged prostate and candidates for surgery will undergo a single treatment for ablation of the prostate using the study device.
- Trial name
- NCT02683980
- Testing
- Lumenis Pulse P120H and Xpeeda side firing fiber
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia
This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1).
- Trial name
- NCT00593593
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline